

#13
Sheet 1 of 1Form PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
(Use additional sheets if necessary)ATTY. DOCKET NO.
GJE-59D1SERIAL NO.
10/199,908

APPLICANT(S): Peter Harrison

FILING DATE
July 18, 2002GROUP ART UNIT
1641 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED
NOV 15 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
SR	AL	9 1 0 1 9 9 0	2/21/91	WO	—	—	— —
SR	AM	9 2 0 1 0 5 9	1/23/92	WO	—	—	— —
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SR	AR	Begent, R.H.J. <i>et al.</i> (1996) "Clinical evidence of efficient tumor targeting based on single - chain Fv antibody selected from a combinatorial library" <i>Nat. Med. (N.Y.)</i> 2(9):979-984.
SR	AS	Jackson, H. <i>et al.</i> (1998) "Antigen specificity and tumor targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity - matured derivatives" <i>Br. J. Cancer</i> 78(2):181-188.
SR	AT	Osborn, Jane K. <i>et al.</i> (1996) "Generation of a panel of related human scFv antibodies with high affinities for human CEA" <i>Immunotechnology</i> 2(3):181-196.
SR	AU	Osborne, J. <i>et al.</i> (April 1999) "Novel super-high affinity sheep monoclonal antibodies against CEA bind colon and lung adenocarcinoma" <i>Hybridoma</i> 18(2):183-191.
SR	AV	Pietersz, G.A. <i>et al.</i> (Jan. 1998) Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody" <i>Journal of Nuclear Medicine</i> 39(1):47-56.

EXAMINER

DATE CONSIDERED

12/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.